Named Bioactive Compounds · Compound
Verbascoside
Moderate Evidencebotanical3 PubMed Studies
Hermetica Superfood Encyclopedia
Verbascoside is a phenylethanoid glycoside found in plants such as Verbascum thapsus, Olea europaea, and Cistanche tubulosa, composed of a caffeic acid ester linked to a hydroxytyrosol-glucose-rhamnose backbone. It exerts antioxidant, anti-inflammatory, and hepatoprotective effects primarily by scavenging reactive oxygen species and suppressing pro-fibrotic signaling pathways in cellular models.
Verbascoside is a polyphenolic phenylethanoid glycoside naturally occurring in over 220 plant species, including mullein (Verbascum species), Lippia citriodora, and Plantago lanceolata. It is typically extracted from medicinal plants using ethanolic or solvent-based methods, yielding standardized extracts containing at least 5% verbascoside.
Clinical evidence for verbascoside is limited to preclinical studies and one small human trial showing decreased platelet aggregation after 100mg daily supplementation for 2 weeks. Most research consists of in vitro and animal studies, including hepatic stellate cell suppression (PMID: 39199153), β-cell protection (PMID: 33302345), and anti-inflammatory effects in immune cells (PMID: 20812283).
The only human clinical study used 100mg oral verbascoside daily for 2 weeks. In vitro studies used 0.8-16 µM for cell protection and 100 µM for anti-inflammatory effects. Standardized extracts typically contain ≥5% verbascoside. Consult a healthcare provider before starting any new supplement.
Verbascoside (also known as acteoside) is a phenylpropanoid glycoside bioactive compound, not a macronutrient-containing food ingredient. It is not a source of meaningful protein, fat, fiber, or micronutrients in typical use. As a pure compound, its molecular weight is 624.59 g/mol (C29H36O15). It is composed of a caffeic acid ester linked to a disaccharide (rhamnose and glucose) backbone. Bioactive concentration in plant sources varies: found at approximately 1–35 mg/g dry weight in Verbascum species, 0.5–10 mg/g in Olea europaea leaves, and up to 20 mg/g in Cistanche tubulosa. In supplement or extract form, standardized preparations typically deliver 50–200 mg per dose. Bioavailability is notably limited due to extensive gut microbial metabolism; oral bioavailability of intact verbascoside is low (estimated <5% in rodent models), with primary metabolites including hydroxytyrosol, caffeic acid, and ferulic acid being the predominant absorbed species detected in plasma. Peak plasma concentration of intact compound after 100 mg oral dose in humans is estimated at low nanomolar range. It is not a caloric contributor at supplemental doses. No relevant vitamin, mineral, or fiber content is associated with the isolated compound form.
Verbascoside inhibits platelet aggregation by interfering with thromboxane A2-mediated signaling and reducing arachidonic acid cascade activity, with in vitro data showing inhibition at concentrations of 1–2 mg/dL in human blood samples. It suppresses hepatic stellate cell activation by downregulating TGF-β1/Smad signaling, reducing expression of alpha-smooth muscle actin (α-SMA) and collagen type I, thereby attenuating liver fibrosis in cell models (PMID: 39199153). Additionally, verbascoside donates hydrogen atoms to neutralize free radicals via its catechol moiety on the caffeic acid unit, inhibiting lipid peroxidation and modulating NF-κB inflammatory transcription.
Human clinical evidence for verbascoside is limited to a single small trial in which participants received 100 mg daily for two weeks, demonstrating a measurable reduction in platelet aggregation. The majority of supporting data derives from in vitro cell studies and animal models examining antioxidant, hepatoprotective, and anti-inflammatory endpoints. No large randomized controlled trials have established efficacy for any indication, and effect sizes from existing studies cannot be reliably extrapolated to clinical practice. The current body of evidence is preliminary and insufficient to support definitive therapeutic claims.
Verbascoside is generally considered well-tolerated in the doses used in the single available human trial (100 mg/day for two weeks), with no serious adverse events reported. Due to its anti-platelet properties, there is a theoretical risk of additive bleeding when combined with anticoagulants or antiplatelet drugs such as warfarin, aspirin, or clopidogrel, and caution is warranted. No formal drug interaction studies exist, and safety data for pregnant or breastfeeding individuals is absent, making use in these populations inadvisable without medical supervision. Individuals with bleeding disorders or those scheduled for surgery should consult a healthcare provider before supplementing.
